Taysha Gene Therapies, Inc. (TSHA)
6.02
-0.18
(-2.90%)
USD |
NASDAQ |
Aug 26, 16:00
6.14
+0.12
(+1.99%)
After-Hours: 20:00
Taysha Gene Therapies Net Income (Quarterly) : -46.64M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -46.64M |
| March 31, 2026 | -42.41M |
| December 31, 2025 | -27.85M |
| September 30, 2025 | -32.73M |
| June 30, 2025 | -26.88M |
| March 31, 2025 | -21.53M |
| December 31, 2024 | -18.78M |
| September 30, 2024 | -25.52M |
| June 30, 2024 | -20.93M |
| March 31, 2024 | -24.06M |
| December 31, 2023 | 47.74M |
| September 30, 2023 | -117.09M |
| June 30, 2023 | -24.60M |
| Date | Value |
|---|---|
| March 31, 2023 | -17.62M |
| December 31, 2022 | -55.72M |
| September 30, 2022 | -26.53M |
| June 30, 2022 | -34.09M |
| March 31, 2022 | -50.32M |
| December 31, 2021 | -50.39M |
| September 30, 2021 | -51.19M |
| June 30, 2021 | -40.93M |
| March 31, 2021 | -32.02M |
| December 31, 2020 | -18.32M |
| September 30, 2020 | -15.04M |
| June 30, 2020 | -21.22M |
| March 31, 2020 | -5.431M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Altimmune, Inc. | -22.82M |
| Protalix Biotherapeutics, Inc. | 3.777M |
| Humacyte, Inc. | -36.80M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 46.64M |
| EPS Diluted (Quarterly) | -0.1264 |
| Enterprise Value | 1.560B |
| Earnings Yield | -7.18% |
| Normalized Earnings Yield | -6.932 |